Proscillaridin A, a cardiac glycoside, is an antiarrhythmic drug that enhances DNMT inhibitors and HDAC inhibitors activity. Combination of decitabine with proscillaridin A produced profound gene expression reprogramming associated with down-regulation of 153 epigenetic regulators including SYMD3 and KDM8. Proscillaridin A was recently identified as a potent anti-HBV agent (IC50 = 7.2?nM).
Molecular cancer therapeutics, 16(2), 397-407 (2016-12-17)
Epigenetic drugs, such as DNA methylation inhibitors (DNMTi) or histone deacetylase inhibitors (HDACi), are approved in monotherapy for cancer treatment. These drugs reprogram gene expression profiles, reactivate tumor suppressor genes (TSG) producing cancer cell differentiation and apoptosis. Epigenetic drugs have
Oxidative medicine and cellular longevity, 2018, 3853409-3853409 (2018-03-27)
Cardiac glycosides are natural compounds used for the treatment of cardiovascular disorders. Although originally prescribed for cardiovascular diseases, more recently, they have been rediscovered for their potential use in the treatment of cancer. Proscillaridin A (PSD-A), a cardiac glycoside component
Sodium taurocholate cotransporting polypeptide (NTCP) has been reported as a functional receptor for hepatitis B virus (HBV) infection. However, HBV could not efficiently infect HepG2 cells expressing NTCP (NTCP-HepG2 cells) under adherent monolayer-cell conditions. In this study, NTCP was mainly
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.